Clinical Trial Update: L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating L-DEP/DEP regimen with a PD-1 antibody for relapse/refractory EBV-HLH is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• L-DEP/DEP regimen
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: NOT_YET_RECRUITING